Metotressato Teva (Methotrexate)

Methotrexate is a folate antagonist that blocks dihydrofolate reductase, an enzyme needed to convert dihydrofolate into tetrahydrofolate. This interruption reduces the synthesis of purines and thymidylate, essential building blocks for DNA and RNA, thereby limiting the proliferation of rapidly dividing immune and cancer cells.

The dosage of Metotressato Teva is individualized by the prescribing clinician based on the specific indication, patient weight, renal and hepatic function, and treatment response. Only a qualified health‑care professional should determine the appropriate dose and administration schedule.

Methotrexate is classified as pregnancy category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and should be discontinued well before conception. Breastfeeding is also not recommended, as the drug can be excreted in milk and affect the infant.

To request Metotressato Teva, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and the necessary import documentation.

Compared with biologic agents such as TNF‑α inhibitors, methotrexate is a small‑molecule drug that can be administered by injection and has a well‑established efficacy in rheumatoid arthritis and psoriasis. It is generally less expensive but may require more laboratory monitoring for hepatic and hematologic toxicity.

Metotressato Teva should be stored at 2‑8 °C in a refrigerator, protected from light and moisture. The product must not be frozen or shaken vigorously. Keep the vial in its original packaging until use to maintain stability.

The medication is supplied as a sterile solution for injection and is given by a qualified health‑care professional via epidural, intrabursal, or intracoronary routes, depending on the therapeutic indication. Administration technique and dosing schedule are determined by the treating physician.

The most critical adverse events include severe liver toxicity, pulmonary fibrosis, and bone‑marrow suppression leading to pancytopenia. These conditions can be life‑threatening and require immediate medical attention. Regular monitoring of liver enzymes, lung function, and blood counts helps mitigate these risks.

Methotrexate is contraindicated in pregnant or nursing women, patients with severe renal or hepatic impairment, active infections, and those receiving live vaccines. Individuals with known hypersensitivity to methotrexate or any component of the formulation should also avoid its use.